GlaxoSmithKline
Company and Pharmaceutical Company
|
GlaxoSmithKline Wins FDA Approval for Cancer Drug...Wins FDA Approval for Cancer Drug by: Zacks.com October 28, 2009 | about: GSK GlaxoSmithKline (GSK) and Denmark-based Genmab received some good news with the US Food and Drug Administration's (FDA) approval for Arzerra (ofatumumab),... In this article: FDA, GlaxoSmithKline, Cancer, Fludarabine, Alemtuzumab, Genmab, Biogen Idec, Cough, and Progressive multifocal leukoencephalopathy |
-
Medical News Today | July 01, 2009
Denmark Patient First To Develop Resistance To Tamiflu
...concern. But with no other known instances of resistance, the CDC isn't ready to stop recommending Tamiflu or Relenza, a similar drug produced by U.K.-based GlaxoSmithKline PLC (GSK), as effective against A/H1N1" (Greil, 6/29). WHO...
In this article: Tamiflu, News & Observer, Denmark, Kenya, Medical advice, and Google map
-
Prime Newswire | October 26, 2009
GSK and Genmab Receive Accelerated Approval for Arzerra
GSK and Genmab Receive Accelerated Approval for Arzerra COPENHAGEN, Denmark and PHILADELPHIA, Oct. 26, 2009 (GLOBE NEWSWIRE) -- Summary: GSK and Genmab have received approval of Arzerra (ofatumumab) from the FDA for CLL that is refractory to...
In this article: Genmab, Fludarabine, Cancer, Alemtuzumab, FDA, Trademark, Ofatumumab, and Safe harbor
-
PR Newswire: All Releases | August 24, 2009
Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
...2003, is headquartered in Denmark with operations in the US. The Company has strategic partnerships with Enzon Pharmaceuticals, GlaxoSmithKline, Wyeth Pharmaceuticals and Shire plc. Please visit www.santaris.com for more information. Shire's...
In this article: Shire plc, Safe harbor, Enzyme replacement therapy, ADHD, Cancer, Private Securities Litigation Reform Act, Oligonucleotide, Nucleotide, Nucleic acid, and Sylvie Gregoire
-
MarketWatch | October 27, 2009
Europe Markets: Europe stocks finish higher; BP climbs, autos fall
...market Arzerra to treat leukemia in patients that have failed to respond to other therapies after it received U.S. regulatory approval late Monday. GlaxoSmithKline and Denmark's Genmab, up 4.2%, developed the drug that was approved under...
In this article: Akzo Nobel, Europe, Leukemia, Renault, Fiat, U.S., Revenue, and Peugeot
-
Declaratory Judgment Action Filed by GSK
Declaratory Judgment Action Filed by GSK COPENHAGEN, Denmark, Oct. 8, 2009 (GLOBE NEWSWIRE) -- Summary: GSK has today filed a declaratory judgment action seeking a declaration that the US Patent 6,331,415 (the "Cabilly" patent) is invalid,...
In this article: Genmab A/S, Filing, Unenforceable, Trademark, Cancer, Ofatumumab, Genentech, Inc., and Copenhagen
-
GlaxoSmithKline and Genmab Announce Results From a Study of Arzerra in Rituximab Refractory Follicular NHL
...Follicular NHL LONDON and COPENHAGEN, Denmark, Aug. 17, 2009 (GLOBE NEWSWIRE) -- Summary: GSK and Genmab announce top-line results from a study of Arzerra (ofatumumab) in rituximab refractory follicular NHL. GlaxoSmithKline (GSK)...
In this article: Genmab, Rituximab, Ofatumumab, NHL, Trademark, Cancer, Safe harbor, and Cough
-
GlaxoSmithKline and Genmab Announce Top-Line Results for Ofatumumab in Rheumatoid Arthritis
...Ofatumumab in Rheumatoid Arthritis COPENHAGEN, Denmark, July 29, 2009 (GLOBE NEWSWIRE) -- Summary: GSK and Genmab announced preliminary top-line results from a Phase III study of ofatumumab in RA. GlaxoSmithKline (NYSE:GSK) and Genmab...
In this article: Ofatumumab, Genmab, Rheumatoid arthritis, Trademark, Methotrexate, Safe harbor, Cancer, and Rash
-
GlaxoSmithKline and Genmab Seek European Marketing Authorisation of Arzerra (Ofatumumab) in Advanced Stage Blood Cancer
...Authorisation of Arzerra (Ofatumumab) in Advanced Stage Blood Cancer COPENHAGEN, Denmark, Feb. 5, 2009 (GLOBE NEWSWIRE) -- GlaxoSmithKline (GSK) and Genmab A/S(OMX:GEN) announced today the submission of a Marketing Authorisation...
In this article: Genmab, Ofatumumab, Cancer, FDA, Trademark, European Medicines Agency, Europe, and Safe harbor
-
Genmab Sells Arzerra Co-Promotion Rights to GlaxoSmithKline
...and commercialize Arzerra. Genmab A/S (Nasdaq:GEN) (Copenhagen:GEN) announced today an amendment to the worldwide agreement to co-develop and commercialize Arzerra(TM) (ofatumumab) with GlaxoSmithKline (GSK). Under the terms of the...
In this article: Genmab A/S, Ofatumumab, FDA, USA, Revenue, Trademark, Cancer, and NHL
Trends
Loading...
More on GlaxoSmithKline
Description from Wikipedia:
GlaxoSmithKline plc (LSE: GSK NYSE: GSK) is a United Kingdom-based pharmaceutical, biological, and healthcare company. GSK is the world's second largest pharmaceutical company and a research-based company with a wide portfolio of pharmaceutical products covering anti-infectives, central nervous system, respiratory, gastro-intestinal/metabolic, oncology, and vaccines products. It also has a Consumer Healthcare operation comprising leading oral healthcare products, nutritional drinks, and over the counter medicines. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index.
- Name:
- GlaxoSmithKline
- Type:
- NYSE: GSK)
- Location:
- Brentford, London, England, UK
- Founded:
- 2000, by merger of Glaxo Wellcome and SmithKline Beecham
- Stock Symbol:
- GSK
- Industry:
- Pharmaceutical
- Key People:
-
- Andrew Witty, Chief Executive
- Dr. Moncef Slaoui, Chairman of Research and Development
- Julian Heslop, Chief Financial Officer
- Sir Chris Gent, Chairman
- Products:
-
- Pharmaceuticals
- Central nervous system, respiratory, antiviral, antibiotic, oncology and emesis, metabolic, cardiovascular, urogenital, and over-the-counter medicines; vaccines; oral and nutritional healthcare products
- Revenue:
- £24.352 billion (2008)
- Operating Income:
- £8.259 billion (2008)
- Net Income:
- £4.712 billion (2008)
- No. of Employees:
- 103,000 (2008)
- Motto:
- "Do more, feel better, live longer"
Explore everything named GlaxoSmithKline...
